129 related articles for article (PubMed ID: 18758913)
1. Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption.
Macnealy MW; Newton HB; McGregor JM; Bell SD; Ray Chaudhury A; Slone HW; Bourekas EC
J Neurooncol; 2008 Dec; 90(3):329-33. PubMed ID: 18758913
[TBL] [Abstract][Full Text] [Related]
2. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
[TBL] [Abstract][Full Text] [Related]
3. Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
Muldoon LL; Lewin SJ; Dósa E; Kraemer DF; Pagel MA; Doolittle ND; Neuwelt EA
Clin Cancer Res; 2011 Apr; 17(8):2207-15. PubMed ID: 21385922
[TBL] [Abstract][Full Text] [Related]
4. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
[TBL] [Abstract][Full Text] [Related]
5. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.
Angelov L; Doolittle ND; Kraemer DF; Siegal T; Barnett GH; Peereboom DM; Stevens G; McGregor J; Jahnke K; Lacy CA; Hedrick NA; Shalom E; Ference S; Bell S; Sorenson L; Tyson RM; Haluska M; Neuwelt EA
J Clin Oncol; 2009 Jul; 27(21):3503-9. PubMed ID: 19451444
[TBL] [Abstract][Full Text] [Related]
6. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
[TBL] [Abstract][Full Text] [Related]
7. Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption.
Vicuna-Kojchen J; Frenkel S; Siegal T; Shalom E; Chowers I; Pe'er J
Br J Ophthalmol; 2008 Feb; 92(2):231-5. PubMed ID: 18227203
[TBL] [Abstract][Full Text] [Related]
8. Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model.
Fortin D; McCormick CI; Remsen LG; Nixon R; Neuwelt EA
Neurosurgery; 2000 Jul; 47(1):199-207. PubMed ID: 10917363
[TBL] [Abstract][Full Text] [Related]
9. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
Hall WA; Doolittle ND; Daman M; Bruns PK; Muldoon L; Fortin D; Neuwelt EA
J Neurooncol; 2006 May; 77(3):279-84. PubMed ID: 16314949
[TBL] [Abstract][Full Text] [Related]
10. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy in conjunction with blood brain barrier disruption in the treatment of primary central nervous system lymphoma].
Kuittinen O; Siniluoto T; Isokangas M; Turpeenniemi-Hujanen T; Peltonen J; Alahuhta S; Sonkajärvi E
Duodecim; 2013; 129(15):1563-70. PubMed ID: 24163974
[TBL] [Abstract][Full Text] [Related]
13. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis.
Fortin D; Gendron C; Boudrias M; Garant MP
Cancer; 2007 Feb; 109(4):751-60. PubMed ID: 17211866
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
[TBL] [Abstract][Full Text] [Related]
16. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival.
Kraemer DF; Fortin D; Doolittle ND; Neuwelt EA
Neurosurgery; 2001 May; 48(5):1033-40; discussion 1040-1. PubMed ID: 11334269
[TBL] [Abstract][Full Text] [Related]
17. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
18. Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot study of the BOMES protocol.
Cheng AL; Yeh KH; Uen WC; Hung RL; Liu MY; Wang CH
Cancer; 1998 May; 82(10):1946-51. PubMed ID: 9587129
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma.
Jahnke K; Muldoon LL; Varallyay CG; Lewin SJ; Brown RD; Kraemer DF; Soussain C; Neuwelt EA
Neuro Oncol; 2009 Oct; 11(5):503-13. PubMed ID: 19158414
[TBL] [Abstract][Full Text] [Related]
20. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
